MindMed Completes 1-for-15 Reverse Share Split Post published:August 27, 2022 Post category:Press Release
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Post published:August 26, 2022 Post category:Press Release
MindMed Strengthens Board with Appointment of Two New Independent Directors Post published:August 12, 2022 Post category:Press Release
MindMed Reports Second Quarter 2022 Financial Results and Business Highlights Post published:August 11, 2022 Post category:Press Release
MindMed Board of Directors Approves Reverse Share Split Post published:August 5, 2022 Post category:Press Release
MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference Post published:August 4, 2022 Post category:Press Release
Mindmed Announces Voting Results for Annual General and Special Meeting Post published:June 1, 2022 Post category:Press Release